List of Excipients in Branded Drug VISIONBLUE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
DORC Dutch Ophthalmic Research Center (International) BV	VISIONBLUE	trypan blue	68803-612	SODIUM CHLORIDE
DORC Dutch Ophthalmic Research Center (International) BV	VISIONBLUE	trypan blue	68803-612	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE
DORC Dutch Ophthalmic Research Center (International) BV	VISIONBLUE	trypan blue	68803-612	SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
DORC Dutch Ophthalmic Research Center (International) BV	VISIONBLUE	trypan blue	68803-612	WATER

VisionBlue Excipient Strategy and Commercial Opportunities in Ophthalmic Surgery

Last updated: August 5, 2026

VisionBlue is a trypan blue 0.06% ophthalmic surgical dye used primarily to stain the anterior lens capsule during cataract surgery. Its commercial value depends less on exclusivity for trypan blue, an established compound, and more on formulation stability, ocular tolerability, sterile single-use packaging, workflow reliability, and surgeon adoption. The strongest commercial opportunities are preservative-free ready-to-use presentations, improved container systems, combination staining products, and expansion into premium cataract and complex anterior-segment procedures.

What is VisionBlue and how is it regulated?

VisionBlue is a sterile ophthalmic solution containing trypan blue at a nominal concentration of 0.06%. It is used to improve visualization of the anterior capsule, particularly when the red reflex is weak or absent, including mature, white, brunescent, traumatic, or complicated cataracts.

Attribute	VisionBlue profile
Active ingredient	Trypan blue
Typical concentration	0.06%
Primary procedure	Cataract surgery
Main use	Anterior capsule staining
Dosage form	Sterile, single-use ophthalmic solution
Administration	Intraocular use during surgery under professional supervision
Commercial format	Small-volume vial or ampoule
Primary manufacturer	DORC International B.V.
U.S. commercial channel	Ophthalmic surgical supply and specialty distribution
Regulatory category	Ophthalmic surgical product; U.S. regulatory treatment should be assessed under device and combination-product rules rather than assumed to follow an NDA/ANDA pathway

The product is not a conventional chronic-use prescription medicine. Its regulatory and commercial profile is closer to a sterile ophthalmic surgical consumable. That distinction affects Orange Book treatment, generic-entry strategy, patent value, and the relevance of biosimilar analysis.

What excipients are used in VisionBlue?

Public product information identifies VisionBlue as a buffered, isotonic, sterile trypan blue solution. The formulation is generally described as containing sodium chloride, phosphate-buffering agents, and water for injection in addition to trypan blue.[1]

Formulation function	Likely excipient class	Commercial purpose
Tonicity adjustment	Sodium chloride	Reduces osmotic stress on intraocular tissues
pH control	Monobasic and dibasic phosphate salts	Maintains product stability and ocular tolerability
Vehicle	Water for injection	Provides a sterile parenteral-grade aqueous medium
Sterility assurance	Sterile manufacturing and container closure	Supports intraocular use without preservatives
Color performance	Controlled trypan blue concentration and impurity profile	Produces consistent capsule staining

The commercial objective is not to add excipients for their own sake. Each component must support one or more of four performance requirements: ocular safety, dye stability, predictable staining, and shelf life.

Why preservative-free formulation matters

Preservatives such as benzalkonium chloride are poorly suited to an intraocular surgical dye. They can create tissue-toxicity concerns, particularly when the product is introduced into the anterior chamber or contacts the corneal endothelium. A preservative-free, single-use format is therefore a central product attribute.

The absence of preservatives also changes the manufacturing burden. The product requires validated aseptic processing or terminal sterilization compatible with trypan blue stability, a robust container-closure system, low particulate levels, and tight control of bioburden and endotoxin.

Why buffer selection is strategically important

Trypan blue is sensitive to formulation conditions that can affect color intensity, degradation, precipitation, and compatibility with ophthalmic surgical materials. Phosphate buffering is commercially attractive because it is familiar to regulators and commonly used in ophthalmic products. Its limitations include potential interaction with certain container materials and the need to control pH and ionic strength across the labeled shelf life.

A reformulated product could evaluate alternative buffers, including citrate or histidine systems, but a change would require evidence that the new buffer does not alter:

• Anterior-segment tolerability
• Corneal endothelial cell viability
• Staining contrast
• Dye adsorption to plastics or tubing
• Sterility and container-closure performance
• Compatibility with viscoelastic agents and irrigation solutions

What formulation patents could protect a VisionBlue competitor?

A patent directed only to trypan blue for capsule staining would likely face substantial prior-art pressure because the compound and its ophthalmic use are established. The stronger patent opportunities are formulation-specific.

Potential formulation claim categories

Claim area	Potential patent value	Key technical requirement
Narrow pH range	Moderate	Demonstrated stability or improved staining
Defined osmolality range	Moderate	Better endothelial safety or reduced inflammation
Low impurity profile	Moderate to high	Analytical proof linking impurities to safety or stability
Improved dye stability	High	Comparative shelf-life data
Oxygen-controlled formulation	Moderate	Reduced degradation under defined packaging conditions
Light-protective packaging	Moderate	Measurable reduction in color loss or degradation
Novel buffer system	Moderate	Unexpected safety, stability, or staining result
Pre-filled delivery device	High	Reliable intraocular delivery and reduced waste
Combination with viscoelastic	High	Demonstrated surgical benefit and compatibility
Dual-dye system	High	Improved visualization across multiple tissue types

A patent estate should focus on measurable performance differences. Broad claims covering "a sterile trypan blue solution for staining the anterior capsule" are more vulnerable than claims tied to a defined impurity limit, stability threshold, package configuration, or delivery method.

Method-of-use patent opportunities

Method-of-use claims could target:

• Capsulorhexis in mature or white cataracts
• Use in eyes with absent red reflex
• Staining under reduced exposure time
• Reduced dye volume
• Use with femtosecond laser-assisted cataract surgery
• Use in pseudoexfoliation, traumatic cataract, or zonular weakness
• Sequential use with capsular tension devices
• Combined anterior capsule and posterior segment visualization

The practical enforceability of these claims may be limited because surgeons, hospitals, and distributors are the relevant actors. Commercial protection is stronger when the method is tied to a proprietary delivery kit or mandatory component.

How strong is the patent estate for VisionBlue?

The patent position for VisionBlue is likely weaker than its commercial position. The active ingredient is old, the use is established, and the product does not depend on a complex molecular structure. Any meaningful protection would likely arise from formulation, manufacturing, packaging, delivery, or a specific method of use.

Patent layer	Expected strength
Trypan blue composition of matter	Low
Basic ophthalmic use	Low
Specific buffered formulation	Moderate, if supported by comparative data
Sterile manufacturing process	Moderate
Low-degradation packaging	Moderate
Single-use delivery system	Moderate to high
Combination surgical kit	Moderate to high
Clinical method claims	Variable
Trademark and brand protection	High relative to ingredient protection

The key diligence issue is whether DORC or another manufacturer has enforceable patents covering the marketed product, rather than whether trypan blue itself is patentable. Public patent searches should cover DORC International, Dutch Ophthalmic USA, Bausch + Lomb, Alcon, Carl Zeiss Meditec, and manufacturers of competing ophthalmic dyes.

When does VisionBlue lose exclusivity?

VisionBlue does not present a conventional small-molecule exclusivity timeline comparable to a new FDA-approved tablet. Its commercial exclusivity is more likely to arise from brand recognition, regulatory clearance, manufacturing qualification, distribution access, and surgeon preference.

Exclusivity mechanism	Relevance to VisionBlue
New chemical entity exclusivity	Not applicable to established trypan blue
Orange Book-listed patents	Must be verified; not automatically expected for a surgical device
Pediatric exclusivity	Not relevant
Orphan-drug exclusivity	Not relevant
Biosimilar exclusivity	Not relevant
Device-market protection	Potentially relevant depending on classification and pathway
Formulation patents	Potentially relevant
Trademark protection	Relevant
Trade secrets	Relevant for impurity control, sterilization, and filling processes

A competitor could potentially enter without infringing a patent by using the same active ingredient with a distinct formulation, container, manufacturing process, or brand. The regulatory pathway would depend on the precise U.S. classification and intended use. An ANDA launch should not be presumed.

What is the Orange Book status of VisionBlue?

VisionBlue should not be analyzed as though it were automatically an Orange Book-listed drug. The Orange Book primarily identifies approved drug products and related patent and exclusivity information. A sterile ophthalmic surgical dye regulated as a medical device may instead be documented through FDA device databases, product labeling, establishment records, and applicable 510(k), PMA, De Novo, or combination-product materials.[2]

For commercial diligence, the relevant questions are:

1. What FDA product code applies?
2. Was the product cleared, approved, or authorized under a device pathway?
3. Is there a drug constituent that triggers combination-product treatment?
4. Are any patents listed in the Orange Book?
5. Does a competing product require a new 510(k), a PMA supplement, or another submission?
6. Can a competitor rely on substantial equivalence, or must it generate new clinical and biocompatibility data?

The answer determines whether a competitor faces a conventional Paragraph IV challenge or a device-equivalence strategy.

What Paragraph IV challenges and generic-entry risks exist?

A Paragraph IV challenge is not the central entry mechanism unless VisionBlue is treated as an approved drug with Orange Book-listed patents. A more realistic competitive-entry pathway may involve:

• A predicate-device or substantial-equivalence argument
• A new device submission for a sterile ophthalmic dye
• A combination-product submission
• A differentiated formulation supported by biocompatibility and stability data
• Hospital or ambulatory-surgery-center contracting
• Private-label supply from a qualified sterile manufacturer

The highest near-term risks are likely to come from products that match the clinical function while competing on price, vial size, supply reliability, or integrated surgical workflow.

Which companies compete with VisionBlue?

The competitive field includes manufacturers of trypan blue ophthalmic dyes and adjacent visualization products. Relevant competitors may include Alcon, Bausch + Lomb, Aurolab, Aurolab-affiliated distributors, and regional ophthalmic-surgical suppliers. Competitive products can differ in concentration, fill volume, packaging, regulatory status, and geographic availability.

Competitive segment	Threat to VisionBlue
0.06% trypan blue equivalents	Direct price and supply competition
Alternative trypan blue concentrations	Procedure-specific substitution
Brilliant Blue G products	Adjacent tissue-visualization competition
Dual-dye products	Premium workflow and differentiation threat
Preloaded injectors	Delivery convenience and waste reduction
Hospital-compounded dyes	Price pressure, with greater quality-control concerns
Private-label products	Distribution-led market share erosion

A competitor with a validated sterile manufacturing platform can enter through contract manufacturing or private-label partnerships without building a large commercial organization.

What commercial opportunities exist for VisionBlue excipients?

The most attractive opportunities are incremental products rather than a simple copy of the existing formulation.

1. Longer shelf life and improved color stability

A formulation with lower degradation, reduced light sensitivity, and stronger package protection could support longer expiry dating and lower distribution losses. This is commercially useful in emerging markets where cold-chain infrastructure is limited, although the product should remain stable at labeled room-temperature conditions.

2. Pre-filled delivery systems

A pre-filled syringe, ampoule, or controlled-dose injector could reduce preparation time, handling errors, and residual product waste. The patent estate would be stronger if the device precisely controls intraocular volume and prevents contact contamination.

3. Combination with viscoelastic agents

A ready-to-use combination of trypan blue and a compatible ophthalmic viscoelastic could simplify the staining step. This concept faces substantial compatibility and regulatory challenges. The product would need to show that the viscoelastic does not dilute the dye, reduce staining contrast, increase endothelial exposure, or interfere with capsulorhexis.

4. Low-volume and low-waste formats

Many procedures require only a small quantity of dye. A lower-fill presentation could reduce cost per case and improve operating-room efficiency. A larger-volume format may be preferable for hospitals seeking standardized inventory across multiple procedure types.

5. Premium complex-cataract kits

A kit containing trypan blue, viscoelastic, cannulas, and capsular-support accessories could shift the product from a commodity dye to a procedural platform. Bundling creates additional contracting value and makes substitution less immediate.

6. Regional manufacturing and licensing

Local sterile filling, packaging, or distribution agreements could improve access in markets with import restrictions or high logistics costs. A licensing partner would likely need validated aseptic capacity, ophthalmic regulatory experience, and established hospital distribution.

No verified public licensing deal, settlement agreement, or active patent litigation should be assumed solely from the VisionBlue brand. These issues require review of corporate transaction records, patent databases, FDA records, and court dockets before an investment or licensing decision.

What manufacturing and IP barriers affect market entry?

The main barriers are technical and regulatory rather than molecular.

• Sterile ophthalmic manufacturing
• Endotoxin and particulate control
• Dye assay and degradation testing
• Container-closure integrity
• Extractables and leachables
• Ocular biocompatibility
• Corneal endothelial safety
• Stability under light and temperature stress
• Compatibility with surgical instruments and viscoelastics
• Validated filling of small-volume sterile units
• Hospital procurement qualification

These barriers favor established ophthalmic manufacturers and contract development and manufacturing organizations with aseptic filling capability. They also create trade-secret value even where patent protection is limited.

What is the revenue exposure and market outlook?

VisionBlue is linked to procedure volume rather than chronic prescription demand. Cataract surgery is the core addressable market, and use is concentrated in cases where capsule visualization has clinical value. Demand is influenced by cataract surgery growth, premium intraocular-lens adoption, surgical training, and hospital purchasing policies.

Revenue exposure is sensitive to:

• Global cataract procedure volumes
• Share of mature or difficult cataract cases
• Product utilization per procedure
• Distributor margins
• Hospital formularies
• Competition from lower-priced trypan blue products
• Supply continuity
• Reimbursement treatment of surgical consumables

The product can support premium pricing when it reduces surgical uncertainty, improves visualization, or integrates into a branded cataract workflow. A stand-alone dye is more exposed to generic-like price competition.

Key Takeaways

• VisionBlue is a sterile 0.06% trypan blue ophthalmic surgical dye used mainly during cataract surgery.
• Its commercial protection is driven by formulation quality, sterile packaging, distribution, and surgeon familiarity rather than new-chemical-entity exclusivity.
• Sodium chloride, phosphate buffers, and water for injection support tonicity, pH control, and ocular tolerability.
• Preservative-free single-use packaging is strategically important for intraocular safety.
• The strongest patent opportunities involve stability, impurity limits, delivery systems, combination kits, and defined surgical methods.
• Orange Book and Paragraph IV analysis may be inapplicable or incomplete if the product is regulated primarily as a medical device.
• The principal generic-entry risk is a sterile, regulatorily acceptable trypan blue equivalent sold through hospital and ophthalmic-surgical channels.
• Commercial expansion opportunities include pre-filled injectors, longer-stability formulations, low-waste units, combination products, and regional licensing.

FAQs

Is VisionBlue a drug or a medical device?

VisionBlue is an ophthalmic surgical product containing a drug-like dye constituent. Its U.S. regulatory treatment should be determined from FDA classification and the applicable product record rather than inferred from the active ingredient alone.

Can a company patent a new VisionBlue formulation?

Yes. A new formulation may be patentable if it provides a non-obvious and measurable improvement in stability, safety, staining performance, packaging, or delivery. A basic trypan blue solution is more vulnerable to prior art.

Are biosimilars relevant to VisionBlue?

No. Biosimilar rules apply to biological products. VisionBlue contains trypan blue, a small-molecule dye, and is not a biologic.

What is the most defensible commercial improvement?

A validated pre-filled, preservative-free delivery system with controlled dosing and improved stability is likely more defensible than a simple reformulation using conventional buffers.

Can hospitals substitute a competing trypan blue product?

Potentially, subject to the competitor's regulatory status, hospital purchasing rules, surgeon preference, product labeling, and demonstrated sterility and ocular safety. Substitution risk is highest where products have equivalent concentration, packaging, and workflow.

References

1. DORC International B.V. (n.d.). VisionBlue 0.06%: Instructions for use and product information. DORC International B.V.

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Device classification and premarket submission pathways. https://www.fda.gov/medical-devices

4. U.S. Food and Drug Administration. (2023). Q1A(R2) stability testing of new drug substances and products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

5. United States Pharmacopeia. (2024). General chapter <1207>: Package integrity evaluation. United States Pharmacopeial Convention.